AVGO Drops 8.7% in a Week — September 2 Prints in Focus as Discretionary Sellers Compound the Move

The lending market has not turned against the stock — that is the clearest counterweight in the data. Short interest is actually falling, dropping 11% over the past week to 1.29% of the free float, one of the lowest readings in the 30-day window. Borrowing costs run at just 0.31% annualised, and availability is effectively unlimited — over 3.8 billion shares remain available to borrow against fewer than 61 million shorted. Whatever is driving the price lower, it is not a short-driven bear campaign. The ORTEX short score of 30.2 sits near the bottom of its recent range, reflecting that same absence of short conviction. Bears are not pressing the move. The selling is coming from somewhere else.

That somewhere else is increasingly well-documented. Monday's ORTEX report flagged two high-profile hedge fund exits on the same day — Druckenmiller and Third Point's Dan Loeb — ahead of a Q3 print 16 sessions out. Those exits are a discretionary signal, not a fundamental one, but they compound. The insider tape over the prior six weeks tells a similar story directionally: the Chief Legal Officer sold $29.2 million of stock in three separate tranches in late June and early July, and Chairman Henry Samueli sold over $67 million across five transactions on June 24 alone. The net insider flow over the past 90 days is a positive $281 million in gross value sold. No offsetting purchases appear in the record. The passive institutional base — BlackRock at 8.4%, Capital Research at 6.7%, Fidelity adding 20 million shares in July — remains intact and growing, but the discretionary and insider layer is clearly reducing exposure ahead of the print.

The analyst community remains structurally bullish but the price action is outrunning the support. The consensus rating is Buy, with 36 buy-equivalent ratings and 7 outperform. JPMorgan's target is $580, BofA's $530, and Jefferies' $550 — all set on June 4 after the prior earnings miss, when the stock was trading near $400 after a 19% single-day drop. With the stock now back at $380, those targets nominally imply 40-50% upside, but their credibility depends entirely on what the September 2 print delivers. The one credible dissent is Macquarie, which downgraded to Neutral on June 4 and set a $437 target — only 15% above where the stock is now, and the most defensible position on the Street given what the tape has done since. DA Davidson's Neutral with a $400 target is similarly conservative. The bull case rests on AI infrastructure demand and VMware software conversion; the bear case — heavy customer concentration and the legacy of acquisition debt — is the same argument that has kept the multiple from fully recovering since the June print. PE is 23.8x and EV/EBITDA is 19x, both drifting lower over 30 days as the price has fallen.

Options positioning adds a mild defensive lean without signalling genuine alarm. The put/call ratio is running at 1.09, marginally above its 20-day average of 1.08 and only 0.66 standard deviations above the mean — well within normal. The 52-week high is 1.23. This is not a panicked options market. It is a cautious one, with buyers of downside protection outnumbering calls but not aggressively so. The z-score would need to move above 2 before this registers as a material signal. For now, options and short interest both say the same thing: the positioning picture is restrained, and the selling is price-action, not a structural build of conviction against the stock.

What to watch in the days ahead is whether the $380 level holds into the September 2 print — the stock is now sitting where it traded immediately after June's post-earnings drop, and how it behaves at that support, alongside whether any further institutional filing disclosures emerge before the Q3 report, will define the setup for what will be the most closely watched semiconductor earnings of the month.